

**European Foundation for the Study of Diabetes**

**EFS**

**The Research Foundation of the  
European Association for the Study of Diabetes**

**Report - 2008**

CONTENTS	PAGE
<b>Introduction</b>	
<b><u>Grant Programmes 2008:</u></b>	
<b>EFSD</b> Clinical Research Grants in the Field of Diabetes	6
<b>EFSD/Amylin</b> Paul Langerhans Grant on the Integrated Physiology of the Entero-Insular Axis and the Brain in Metabolic Homeostasis	7
<b>EFSD/Chinese Diabetes Society/Lilly</b> Collaborative Diabetes Research Programme	8
<b>EFSD/GlaxoSmithKline</b> Programme for the Study of Metabolic Toxicity in Diabetes	9
<b>EFSD/JDRF/Novo Nordisk</b> European Programme in Type 1 Diabetes Research	10
<b>EFSD/LifeScan</b> European Studies on Glucose Monitoring	12
<b>EFSD/Lilly</b> European Diabetes Research Programme	13
<b>EFSD/Merck Sharp &amp; Dohme (MSD)</b> European Studies on Beta Cell Function and Survival: Basic Research Programme	14
<b>EFSD/Merck Sharp &amp; Dohme (MSD)</b> European Studies on Islet Cell Function and Survival: Clinical Research Programme	15
<b>EFSD/Novartis</b> European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction	16
<b>EFSD/Novo Nordisk</b> European Clinical Research Programme in Adolescents with Type 2 Diabetes	17
<b>EFSD/Pfizer</b> European Programme for Research into Cardiovascular Risk Reduction in Patients with Diabetes	18
<b>EFSD/sanofi-aventis</b> European Programme: The Endocannabinoid System from Bench to Bedside and European Programme: Macrovascular Complications and Blood Glucose Abnormalities	19

**Fellowships 2008:**

<b>EFSD Albert Renold</b> Travel Fellowships supported by <b>Merck Sharp &amp; Dohme (MSD)</b>	22
<b>EFSD/Chinese Diabetes Society/Lilly</b> Research Fellowships	23
<b>EFSD/Lilly</b> Research Fellowships in the Fields of Metabolism and Complications of Diabetes	24

**New Programmes 2009:**

<b>EFSD</b> New Horizons	26
<b>EFSD/D-Cure</b> Young Investigator Awards for Collaborative Diabetes Research between Israel and Europe	27
<b>EFSD/Lilly</b> Mental Health and Diabetes Programme	28
<b>EFSD/Roche</b> EFSD/Roche Programme for the Development and Characterisation of Translational Preclinical Models for Type 2 Diabetes	29
<b>EFSD/sanofi-aventis</b> European Research Programme in Micro- and Macrovascular Complications of Diabetes	30

*Note: the above relates solely to programmes which have been officially agreed to date.*

---

<b>EFSD Review Committee Members</b>	31
<b>EFSD Executive Committee and Administration</b>	32

European Foundation for the Study of Diabetes

# EFSD

The Research Foundation of the  
European Association for the Study of Diabetes

In 1999 the European Association for the Study of Diabetes (EASD) created its own Foundation - the European Foundation for the Study of Diabetes (EFSD) - in order to support more actively diabetes research in Europe and to serve even more effectively the goals of EASD, which are: to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge, and to facilitate its application.

EFSD is a non-profit foundation, which seeks to support the highest quality research in Europe to find a cure for all types of diabetes and associated complications and to prevent their onset. EFSD aims to co-operate with other government and non-government agencies in order to increase funding in European diabetes research as a means of achieving its goals. Through its various activities and programmes, the Foundation also strives to enhance awareness in Europe of the severity and magnitude of this devastating disease. It is the ambition of the Executive Committee to develop EFSD as the main European funding agency for diabetes research.

The Foundation is closely related to EASD; it is governed exclusively by the Executive Committee of EASD, which itself is under the close supervision of the EASD Council and General Assembly. The Foundation operates on a strictly non-profit basis under the control of the relevant authorities in Germany.

### EFSD and its partners bring over Euro 53 Million to European diabetes research

In order to foster diabetes research at the highest level in Europe, EFSD has entered into innovative partnerships with other foundations and with industry. Through such partnerships, as well as its own stand-alone funding initiatives, to date EFSD has committed over **Euro 53 million** to diabetes research in Europe.

Further information on EFSD Award Programmes is available on the website of the Foundation: [www.EuropeanDiabetesFoundation.org](http://www.EuropeanDiabetesFoundation.org). An RFA (request for applications) for each Programme is printed in *Diabetologia* (the official journal of EASD), and announced in the monthly e-mail sent to EASD members.

All applications are subject to rigorous peer review by a fully independent panel of leading experts in the field, and awards are based on scientific merit. Applications from non-profit organisations are welcome from Europe or any associated country as well as named non-European countries in the context of collaborative research programmes.

**European Foundation for the Study of Diabetes**

**EFS****D**

**The Research Foundation of the  
European Association for the Study of Diabetes**

**GRANT**

**PROGRAMMES**

**2008**

# EFSD

## Clinical Research Grants in the Field of Diabetes

### Plan

The EFSD Clinical Research Grants Programme was created to stimulate research into all aspects of diabetes, but with particular reference to epidemiology/genetics of prediabetes, diabetes and its micro- and macrovascular complications, pathophysiology and clinical aspects including vascular physiology and obesity.

### Funding Commitment and Instruments

Starting in 2007, this stand-alone EFSD Programme will commit a total of **Euro 3.6 million** towards clinical research in diabetes, with awards of up to Euro 300,000 over a period of up to three years, dependent upon the needs of the project.

### Awards in 2008

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

Daniel Cuthbertson:	University of Liverpool - U.K.
Åke Lernmark:	Lund University - Sweden
Gottfried Rudofsky:	University of Heidelberg - Germany
Iris Shai:	Ben Gurion University - Beer-Sheva, Israel

# EFSD and Amylin

## Paul Langerhans Grants on the Integrated Physiology of the Entero-Insular Axis and the Brain in Metabolic Homeostasis

### Background

Amylin Pharmaceuticals Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialisation of innovative medicines. The company was founded in 1987 and since then has built a strong foundation on research and development.

### Plan

EFSD and Amylin established a partnership in 2005 to provide grants for studies on the integrated physiology of the entero-insular axis and the brain in metabolic homeostasis. In 2008, the Programme offered grants of up to Euro 100,000 for basic research and up to Euro 300,000 for clinical research aimed at advancing current knowledge and to stimulate European research in this domain.

### Funding Commitments and Instruments

Since its creation in 2005 and with additional funds committed in 2008, the total funding commitment of the partnership is now **Euro 700,000**, made available as research grants.

### Awards in 2008

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

Michael Lehrke:	University of Munich - Germany
Edwin Parlevliet:	Leiden University Medical Center - The Netherlands
Bernard Portha:	University Paris Diderot - France
Qimin Zhang:	Karolinska Institutet - Stockholm, Sweden

**EFSD**  
and the  
**Chinese Diabetes Society**  
and  
**Lilly**

## **Programme for Collaborative Diabetes Research between China and Europe**

### **Background**

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Founded in 1991, the Chinese Diabetes Society conducts public education programmes, epidemiological surveys and research in China. The mission of CDS is to prevent and treat diabetes and provide information to help educate people living with diabetes, their families, health care professionals, and the public about this disease.

### **Plan**

This new partnership Fund will target collaborative research endeavours between European and Chinese research centres and/or individual investigators in the area of diabetes and its complications.

### **Funding Commitment and Instruments**

Total funding of **Euro 1.2 million** has been committed from 2008 – 2010. Two basic science research grants in the sum of up to Euro 100,000 and one clinical outcomes research grant in the sum of up to Euro 200,000 will be made available annually, for research to be carried out in China in collaboration with a European research institution.

### **Awards in 2008**

The deadline for applications was September 2008, and awards will be made in February 2009.

# EFSD and GlaxoSmithKline

## Programme for the Study of Metabolic Toxicity in Diabetes

### Background

Headquartered in the UK, and with operations based in the US, GlaxoSmithKline is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. Its mission is to improve the quality of human life by enabling people to do more, feel better and live longer.

### Plan

EFSD and GlaxoSmithKline have established a new partnership intended to stimulate and accelerate European research aimed at all aspects of metabolic cytotoxicity, with particular focus on molecular mechanisms of glucotoxicity and lipotoxicity, the mechanism of dysfunction and death of islet cells induced by hyperglycaemia and/or dyslipidaemia and the mechanism of insulin resistance induced by hyperglycaemia and/or dyslipidaemia.

### Funding Commitment and Instruments

Established in 2007 and since renewed, the total commitment of this partnership is **Euro 1 million**, made available as grants each of up to Euro 100,000.

### Awards in 2008

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

Anja Krones-Herzig:  
Noel Morgan:  
Romeo Ricci:  
Patrick Schrauwen:

German Cancer Research Center - Heidelberg, Germany  
Peninsula College - Plymouth, U.K.  
Institute of Cell Biology - Zurich, Switzerland  
Maastricht University - The Netherlands

**EFSD**  
and  
**Juvenile Diabetes Research Foundation**  
**(JDRF)**  
and  
**Novo Nordisk A/S**

## **European Programme in Type 1 Diabetes Research**

### **Background**

The mission of the Juvenile Diabetes Research Foundation International (JDRF) is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novo Nordisk has companies and information offices in more than 60 countries.

### **Plan**

The EFSD/JDRF/Novo Nordisk Programme in Type 1 Diabetes Research aims to foster multi-disciplinary research targeted at finding a cure for type 1 diabetes and its complications. The specific goals of the Programme are: to promote the highest quality of basic and clinical biomedical research in Europe and its associated countries applicable to type 1 diabetes, to expedite the practical application of scientific advances in our understanding of the aetiology, pathogenesis, treatment and prevention of type 1 diabetes and its complications, to encourage clinical translational research bridging the bench and the bedside, and to increase awareness of type 1 diabetes research throughout Europe.

### **Funding Commitment and Instruments**

The EFSD/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research was established in 2001 and has since been renewed twice, with a combined commitment of **Euro 11.75 million**. Grants of up to Euro 100,000 are available each year.

**Awards in 2008**

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

Susanna Cardell:	University of Gothenburg - Sweden
Eugenia Carvalho:	University of Coimbra - Portugal
Michael Christie:	King's College London - U.K.
Lena Claesson-Welsh:	University of Uppsala - Sweden
Allan Flyvbjerg:	Aarhus University Hospital - Denmark
Agnès Lehen:	Hôpital Saint Vincent de Paul - Paris, France
Timo Otonkoski:	University of Helsinki - Finland
Ana Maria Wägner:	Servicio Canario de Salud - Gran Canaria, Spain
Yehiel Zick:	Weizmann Institute of Science - Rehovot, Israel

# EFSD and LifeScan

## European Studies on Glucose Monitoring

### Background

For more than two decades LifeScan has been committed to improving the quality of life for people with diabetes. LifeScan helped bring blood glucose testing out of the laboratory and into the hands of patients.

### Plan

The EFSD/LifeScan Awards are intended to stimulate and accelerate European research aimed at improved understanding of the optimal use of glucose monitoring tools, both in type 1 and type 2 diabetes.

### Funding Commitment and Instruments

The partnership was launched in 2005, and with additional funding in 2007, has committed a total of **Euro 1.2 million**, offered in the form of research grants. In 2008, up to Euro 500,000 was offered for each individual research project.

### Awards in 2008

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

J. Hans De Vries:

Academic Medical Center - Amsterdam, The Netherlands

Elisabeth Mathiesen:

Faculty of Health Sciences - Copenhagen, Denmark

# EFSD and Lilly

## European Diabetes Research Programme

### Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

### Plan

The EFSD/Lilly European Diabetes Research Programme is established within the frame of the EFSD/Lilly Fund. The goals of the Fund are: to promote increased European research in diabetes, support training and mobility programmes in diabetes research for young clinicians and scientists, and increase awareness of the burden of diabetes and its complications throughout Europe. Launched in 2003 and renewed in 2006, the Fund has now reached a total commitment of **Euro 3.8 million** to fund its various activities, including research grant and fellowship programmes.

### Funding Commitment and Instruments

To date, the EFSD/Lilly Fund has contributed **Euro 2.1 million** towards the EFSD/Lilly Diabetes Research Programme, in the form of grants of up to Euro 100,000 each.

### Awards in 2008

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

Peter Carmeliet:	Flanders Institute for Biotechnology - Zwijnaarde, Belgium
Miriam Cnop:	Free University Brussels - Belgium
Stephan Herzig:	Deutsches Krebsforschungszentrum Heidelberg - Germany
Claes Wollheim:	University of Geneva - Switzerland

# **EFSD** and **Merck Sharp & Dohme (MSD)**

## **European Studies on Beta Cell Function and Survival: Basic Research Programme**

### **Background**

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

### **Plan**

These Programme awards are intended to stimulate and accelerate European research into all aspects of beta cell function and survival, with particular emphasis on the following: increasing beta cell mass/function, mechanisms of glucose-stimulated insulin secretion, mechanisms of beta cell dysfunction, including beta cell gluco- and lipotoxicity, non-invasive imaging of beta cells, and beta cell intermediary metabolism.

### **Funding Commitment and Instruments**

This partnership Programme was established in 2005 and renewed in 2007 for a total commitment of **Euro 3.2 million**, to be distributed in the form of grants, each of up to Euro 100,000.

### **Awards in 2008**

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

Bernadette Breant:	University Pierre et Marie Curie - Paris, France
Harry Heimberg:	Free University Brussels - Belgium
Patrick Jacquemin:	Louvain Catholic University - Brussels, Belgium
Kathrin Maedler:	University of Bremen - Germany
Stephan Speier:	Karolinska Institutet - Stockholm, Sweden
Emmanuel Van Obberghen:	Nice University Hospital - France

# **EFSD and Merck Sharp & Dohme (MSD)**

## **European Studies on Islet Cell Function and Survival: Clinical Research Programme**

### **Background**

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

### **Plan**

These Programme awards are intended to stimulate and accelerate European research into clinical aspects of islet cell function and survival. Areas of particular interest include alterations in islet cell mass/function in diabetes and obesity, non-invasive imaging of islet cells, mechanisms of beta cell dysfunction in type 2 diabetes including beta cell gluco- and lipotoxicity, preservation or prevention of further loss of beta cell functional mass in individuals with impaired glucose tolerance, type 2 diabetes or early type 1 diabetes, methods for improving survival of transplanted islets or beta cells, and genetic defects that elucidate beta cell dysfunction in type 2 diabetes

### **Funding Commitment and Instruments**

This partnership Programme was established in 2008 for a total commitment of **Euro 2.7 million** to be distributed in the form of grants, each of up to Euro 300,000.

### **Awards in 2008**

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

Michaela Diamant:	Amsterdam Free University Medical Centre – The Netherlands
Antonio Secchi:	Fondazione Centro San Raffaele - Milan, Italy

# EFSD and Novartis A/S

## European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction

### Background

Novartis is a world leader in the research and development of products to protect and improve health and well-being. Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz.

### Plan

The EFSD/Novartis European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction was created in order to stimulate and accelerate European clinical research into all aspects of pancreatic islet dysfunction. This Programme targets the clinical physiology and natural history of pancreatic islet dysfunction as it pertains to diabetes and other dysglycaemic conditions.

### Funding Commitment and Instruments

A total of **Euro 1.2 million** has been made available to fund research grants up to Euro 200,000 each.

### Awards in 2008

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

Riccardo Bonadonna:  
Harald Klein:

University of Verona - Italy  
Ruhr-University Bochum - Germany

# EFSD and Novo Nordisk A/S

## European Clinical Research Programme in Adolescents with Type 2 Diabetes

### Background

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 60 countries.

### Plan

The goals of the Programme are to promote the highest quality of clinical medical research in Europe and its associated countries applicable to type 2 diabetes in adolescents; to expedite the practical application of scientific advances in our understanding of the psycho-social conditions, aetiology, pathogenesis, treatment and prevention of type 2 diabetes and its complications in adolescents, and to encourage clinical translational research bridging bench and bedside.

### Funding Commitments and Instruments

This Programme replaces the EFSD/Novo Nordisk Programme in Type 2 Diabetes, with a combined total of **Euro 7.5 million**. Grants of up to Euro 300,000 are made available each year.

### Awards in 2008

Based on the recommendations of the Review Committee, the Programme Board made the following award:

Reinhard Holl:

University of Ulm - Germany

# **EFSD and Pfizer**

## **European Programme for Research into Cardiovascular Risk Reduction in Patients with Diabetes**

### **Background**

Pfizer is one of the world's leading healthcare companies, providing human and animal pharmaceuticals, as well as consumer products. As part of its commitment to the care of patients with diabetes, Pfizer is dedicated to supporting research that will help identify ways to reduce cardiovascular risk, further our understanding of optimal treatment options, and ultimately improve the lives of people with diabetes.

### **Plan**

The key objective of this research partnership is to understand better what best impacts cardiovascular risk reduction in patients with diabetes. Research proposals should aim to evaluate the impact of any aspect of the following on CV risk reduction in diabetes: educational tools, programmes and strategies, risk assessment tools/screening and diagnostic procedures and clinical interventions. This Programme replaces the EFSD/Pfizer Resource Awards for European Diabetes Research.

### **Funding Commitments and Instruments**

Since its establishment in 2004 with the EFSD/Pfizer Resource Awards Programme, a total of **Euro 1.8 million** has been made available. In the current programme, Euro 1.2 million has been allocated to fund research grants up to Euro 300,000 each.

### **Awards in 2008**

Knut Borch-Johnsen:  
Marju Orho-Melander:

Steno Diabetes Center - Gentofte, Denmark  
Lund University - Malmö, Sweden

# EFSD and sanofi-aventis

## **European Programmes for the Study of:**

### **The Endocannabinoid System from Bench to Bedside and Macrovascular Complications and Blood Glucose Abnormalities**

#### **Background**

The sanofi-aventis Group is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas, and produces several medicines to treat diabetes including insulin. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis.

#### **Plan**

EFSD and sanofi-aventis have created two European Programmes for studies in the following areas:

- The Endocannabinoid System from Bench to Bedside focuses on the integration of central and peripheral control of fuel and energy metabolism and its role in the pathophysiology of multiple cardiometabolic risk factors, including insulin resistance and type 2 diabetes. This programme supports both basic and clinical research.
- Macrovascular Complications and Blood Glucose Abnormalities encourages studies measuring parameters of blood glucose control, cardiac function, endothelial function, lipid metabolism or evaluating macrovascular complications in patients with a chronic cardiovascular disease, or experiencing an acute cardiovascular event, before and after insulin treatment compared to other treatments, or comparing different insulin treatment regimens. Studies focusing on pharmaco-epidemiology and patient care are also relevant to this Programme.



**European Foundation for the Study of Diabetes**

**EFSD**

**The Research Foundation of the  
European Association for the Study of Diabetes**

**FELLOWSHIPS**

**2008**

# EFSD

## Albert Renold Fellowships

Supported by an unrestricted educational grant  
from **Merck Sharp & Dohme (MSD)**

Albert Renold Fellowships, each of up to Euro 6,000, enable young scientists to travel to and stay at other institutions in order to learn new techniques in basic or clinical diabetes research. The duration of the stay should not exceed three months. In 2009 these Fellowships will offer awards of up to Euro 7,000 each.

Albert Renold Fellowships are available throughout the year, and a decision is usually made within a few weeks of applying.

In 2008 the following Fellowships were awarded:

Elisa Astorri: travelled to Bart's and the London School of Medicine - UK  
Dijing Zhi: travelled to Karolinska Institutet - Stockholm, Sweden  
Michael Hühn: travelled to Washington University - St Louis, USA  
David Funda: travelled to Bartholin Institute - Copenhagen, Denmark  
Thomas Sherer: travelled to Mount Sinai Medical School - New York, USA  
Tina Rönn: travelled to Wellcome Trust Centre - Oxford, UK  
Mei Zhang: travelled to King's College - London, UK  
Kim Zarse: travelled to University of Columbia - New York, USA  
Mandy van Hoek: travelled to Wellcome Trust Centre - Oxford, UK  
Audrey Koitka: travelled to University of Ulm - Germany  
Emily Williams: travelled to University of Melbourne - Australia  
Nadine Sauter: travelled to Joslin Center - Boston, USA  
Kathrin Hatlapatka: travelled to Uppsala University - Sweden  
Ágnes Jermendy: travelled to Harvard Medical School - Boston, USA  
Ana Isabel Marques Duarte: travelled to Lund University - Malmö, Sweden  
Emanuela Martinuzzi: travelled to Royal Melbourne Hospital - Australia  
Esther van 't Riet: travelled to School of Public Health - Boston, USA  
Jade McCulloch: travelled to University of Geneva - Switzerland

**EFSD**  
and the  
**Chinese Diabetes Society**  
and  
**Lilly**

## **Research Fellowships**

The objective of the EFSD/CDS/Lilly Research Fellowships is to encourage collaborative research in the field of diabetes. Applications for fellowships may be accepted from applicants from China for study in a recognised research institution in Europe or its associated countries. Details of the partner organisations may be found under “EFSD/CDS/Lilly Collaborative Research Programme”.

Two Fellowships of up to Euro 25,000 each are awarded annually. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

Total funding of **Euro 300,000** has been committed from 2008 – 2010 for this Fellowship Programme.

The deadline for applications was September 2008, and awards will be made in February 2009.

# EFSD and Lilly

## Research Fellowships

The objective of the EFSD/Lilly Research Fellowships is to encourage innovative research in the fields of metabolism and complications of diabetes, and to promote excellence in medical education.

Two Fellowships of up to **Euro 50,000** each are awarded annually. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

These Fellowships are available for the period 2006 – 2008 inclusive as part of the EFSD/Lilly European Diabetes Research Fund, further details of which may be found under “EFSD/Lilly Diabetes Research Programme”.

In 2008 the following Fellowships were awarded:

Ferdinando Giacco:	Federico II University - Naples, Italy
Lina Lauffer:	University of Toronto - Canada

**European Foundation for the Study of Diabetes**

**EFS**

**The Research Foundation of the  
European Association for the Study of Diabetes**

**NEW**

**PROGRAMMES**

**2009**

# EFSD

## **New Horizons Collaborative Research Initiative**

### **Plan**

There is a rich history of diabetes research throughout Europe and its associated states. Historically, however, funding for such research tends to be unevenly distributed.

The Foundation now seeks to redress in part this imbalance and to foster inter-regional collaboration in diabetes research throughout Europe by making available grants through the EFSD New Horizons Collaborative Research Initiative

This Programme has been created to foster inter-regional collaboration in diabetes research throughout Europe on a competitive basis. It is open to investigators working in institutions in the following countries and proposing to collaborate with an investigator from a European country not on this list: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Hungary, Latvia, Lithuania, FYRo Macedonia, Moldavia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, and Ukraine.

### **Funding Commitment and Instruments**

Up to **Euro 1.2 million** has been made available for the period 2009 - 2011 to fund basic and clinical research grants.

### **Awards in 2009**

The deadline for applications is 31 January 2009, with an anticipated award date of April 2009.

# **EFSD and D-Cure**

## **Young Investigator Awards for Collaborative Diabetes Research between Israel and Europe**

### **Background**

D-Cure Diabetes Care in Israel R.A. (D-Cure) is a recently established non-profit organisation that aims to advance basic and clinical research into diabetes in Israel. This EFSD/D-Cure Programme is further supported by a charitable donation from another Israeli Foundation and the Berlin Charitable Trust.

### **Plan**

This partnership programme encourages new projects aimed at advancing current knowledge in type 2 diabetes which are undertaken by young investigators working in Israel, in collaboration with an investigator working in another country in Europe.

### **Funding Commitment and Instruments**

A total funding commitment of US\$ 350,000 has been made available in 2009 for research projects totalling up to US\$ 75,000 each.

### **Awards in 2008**

The deadline for Letters of Intent is 16 January 2009, with an anticipated award date of June 2009.

# EFSD and Lilly

## Mental Health and Diabetes Programme

### **Background**

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Eli Lilly and Company is in Indianapolis, Indiana, USA.

### **Plan**

The EFSD/Lilly Mental Health and Diabetes Programme is intended to stimulate and accelerate European research aimed at clinical investigations into improved care of patients with diabetes and mental diseases including all forms of depression, schizophrenia and Alzheimer's. Special emphasis should be given to improving the co-operation between psychiatric and diabetes care.

### **Funding Commitment and Instruments**

A funding commitment of **Euro 250,000** has been made available to fund one grant in 2009.

### **Awards in 2009**

The deadline for applications is 15 September 2009, with an anticipated award date of December 2009.

# **EFSD and Roche**

## **Programme for the Development and Characterisation of Translational Preclinical Models for Type 2 Diabetes**

### **Background**

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life.

### **Plan**

This partnership Programme aims to encourage the development and characterisation of translational preclinical models for type 2 diabetes. One particular focus of the Programme will be the development of models of cardiomyopathies and chronic kidney disease.

### **Funding Commitment and Instruments**

A total commitment of Euro 500,000 will be made available in 2009 for research grants totalling up to Euro 100,000 each.

### **Awards in 2009**

To be announced.

# **EFSD and sanofi-aventis**

## **European Research Programme in Micro- and Macrovascular Complications of Diabetes**

### **Background**

The sanofi-aventis Group is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas, and produces several medicines to treat diabetes including insulin. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis.

### **Plan**

In 2009 a new EFSD/sanofi-aventis Programme has been established which will focus on vascular complications of diabetes.

### **Funding Commitment and Instruments**

A total of **Euro 1.2 million** has been made available to fund basic research projects up to Euro 100,000 and clinical research projects up to Euro 400,000.

### **Awards in 2009**

To be announced.

## EFSD Review Committee Members

EFSD is most grateful to the following colleagues who served on the various review committees of the 2008 partnership programmes:

Amar Abderrahmani	(CH)	Agnés Lehuen	(F)
Arne Astrup	(DK)	Beat Lutz	(D)
Angelo Avogaro	(I)	Johannes Maassen	(NL)
Clifford Bailey	(UK)	Aldo Maggioni	(I)
Angelika Bierhaus	(D)	Piero Marchetti	(I)
Henning Beck-Nielsen	(DK)	Michel Marre	(F)
Polly Bingley	(UK)	Ulrich Müller	(D)
Christian Boitard	(F)	Andrea Natali	(I)
Fatima Bosch	(E)	Michael Nauck	(D)
Luc Bouwens	(B)	Kenneth Paterson	(UK)
Rémy Burcelin	(F)	John Pickup	(UK)
Bernard Charbonnel	(F)	Massimo Porta	(I)
Miriam Cnop	(B)	Romano Regazzi	(I)
Jens Sandahl Christiansen	(DK)	Marian Rewers	(USA)
Jacqueline Dekker	(NL)	Gabriele Riccardi	(I)
Stefano del Prato	(I)	Carani Sanjeevi	(S)
Vincenzo di Marzo	(I)	André Scheen	(B)
Marc Donath	(CH)	Giorgio Sesti	(I)
Jorge Ferrer	(E)	Åke Sjöholm	(DK)
Allan Flyvbjerg	(DK)	Ulf Smith	(S)
Ramon Gomis de Barbara	(E)	Giatgen Spinas	(CH)
Valdemar Grill	(N)	Philippe-Gabriel Steg	(F)
Hans-Peter Hammes	(D)	Coen Stehouwer	(NL)
Kristian Hanssen	(N)	Markus Stoffel	(CH)
Hans-Ulrich Häring	(D)	Michael Stumvoll	(D)
Stephan Herzig	(D)	Charles Thivolet	(F)
Jean-Christophe Jonas	(B)	Tiina Tuomi	(FIN)
Peter Jones	(UK)	Hubert Vidal	(F)
Fredrik Karpe	(UK)	Antonio Vidal-Puig	(UK)
Harald Klein	(D)	Mark Walker	(UK)
Markku Laakso	(FIN)	Dan Ziegler	(D)
Martine Laville	(F)		

# EFSD EXECUTIVE COMMITTEE and ADMINISTRATION

## Executive Committee:

<b>President:</b>	U Smith - Göteborg
<b>Vice President:</b>	C Boitard - Paris
<b>Vice President:</b>	A Boulton - Manchester
<b>Honorary Secretary:</b>	M Stumvoll - Leipzig
<b>Honorary Treasurer:</b>	G Spinass - Zürich
<b>Editor in Chief - <i>Diabetologia</i>:</b>	E Gale - Bristol
<b>Chairman PGESC:</b>	J Nolan - Dublin

---

**Chairman - EFSD:** P A Halban - Geneva

**Scientific Board:**  
S Amiel - London  
E Ferannini - Pisa  
J Ferrer - Barcelona  
M Laakso - Kuopio  
M Walker - London

**Executive Director:** V Jörgens - Düsseldorf  
**Administrators:** S Köhnen - Düsseldorf  
K Sommer - Düsseldorf

The European Foundation for the Study of Diabetes (EFSD)  
Rheindorfer Weg 3  
40591 Düsseldorf, Germany

Tel: + 49 211 75 84 69-0 Fax: + 49 211 75 84 69-29

[www.EuropeanDiabetesFoundation.org](http://www.EuropeanDiabetesFoundation.org)

Email: [Foundation@easd.org](mailto:Foundation@easd.org)

### **Bank details**

Europäische Stiftung für Diabetesforschung – EFSD  
Dresdner Bank  
Königsallee 37  
40212 Düsseldorf, Germany

Account / Konto: 600 2146 00 Code / BLZ: 300 800 00

SWIFT / BIC: DRES DE FF 300

IBAN: DE31 3008 0000 0600 2146 00

EFSD is registered as a non-profit Foundation in Düsseldorf, Germany under registration number: 15.2.1-St.767  
and at the Inland Revenue in Düsseldorf, Germany under tax number: 106/5744/1547

**The EFSD Accounts for the fiscal year 2007 were submitted to the German Inland Revenue. Following detailed evaluation, a Certificate was issued endorsing the status of EFSD as a charity. This Certificate is held on file at the EFSD office and a copy can be made available upon request.**